The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | TROP2-high tumors are associated with cold immune signatures
Jessy Deshane, PhD, the University of Alabama at Birmingham, Birmingham, AL, shares insights into TROP2 expression and the tumor microenvironment from a paired spatial transcriptomic and proteomic mapping study in non-small cell lung cancer (NSCLC) tissue. TROP2-high tumors were found to be cold immune environments, highlighting the potential for TROP-directed antibody-drug conjugates (ADCs) for these patients. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
